The agreement will see Agenix transfer the manufacturing process developed by the company to Diosynth Biotechnology for further process refinement and commercial scale manufacturing.
“This is a very important milestone in the ThromboView program and we are pleased to have engaged an experienced company with a successful track record in the transfer and manufacture of biotechnology products,” said Agenix’ managing director, Donald Home. “Given the promising results we have seen from the clinical trials completed so far we remain confident in both the clinical need and performance for this product”
ThromboView blood clot-imaging project is currently undergoing phase II human trials in the US and Canada. The technology uses radio-labeled antibodies to locate blood clots in the body, and could revolutionize the US $3 billion global clot diagnostic imaging market.